Julie Zrubek

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Arthritis & Rheumatism · 2009 · 603 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Edward Keystone, Mark C. Genovese, Lars Klareskog et al. · Annals of the Rheumatic Diseases · 2008 · 541 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trial

Arthur Kavanaugh, Désirée van der Heijde, Iain B. McInnes et al. · Arthritis & Rheumatism · 2012 · 209 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE

Alex C. Spyropoulos, Julie Zrubek, Walter Ageno et al. · Thrombosis and Haemostasis · 2016 · 74 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACH

Wallace Crandall, Jeffrey S. Hyams, Subra Kugathasan et al. · Journal of Pediatric Gastroenterology and Nutrition · 2009 · 67 citations

Medicine, Clinical Sciences, Pediatrics +15